These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Author: Suzuki Y, Sato S.
    Journal: Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275.
    Abstract:
    Glucocorticoids were widely used for the treatment of various disorders. Therefore, the management of glucocorticoid-induced osteoporosis (GIOP) is referred to doctors who take care of underlying diseases. Since glucocorticoid-induced bone loss is most rapid during the initial 3-6 months, primary prevention of bone loss is especially important.The Japanese Society of Bone and Mineral Metabolism have devised a guideline for the management of GCOP and bisphosphonates play a central role for the primary and secondary prevention of GIOP. Human PTH (1-34) , teriparatide is possible another beneficial drug in addition to bisphosphonates.
    [Abstract] [Full Text] [Related] [New Search]